[go: up one dir, main page]

WO2005047530A3 - Procede de dosage de composes modulant l'activite du recepteur zeta de proteine tyrosine phosphatase (ptpr$g(j)) - Google Patents

Procede de dosage de composes modulant l'activite du recepteur zeta de proteine tyrosine phosphatase (ptpr$g(j)) Download PDF

Info

Publication number
WO2005047530A3
WO2005047530A3 PCT/US2004/037514 US2004037514W WO2005047530A3 WO 2005047530 A3 WO2005047530 A3 WO 2005047530A3 US 2004037514 W US2004037514 W US 2004037514W WO 2005047530 A3 WO2005047530 A3 WO 2005047530A3
Authority
WO
WIPO (PCT)
Prior art keywords
ptprzeta
modulate
activity
protein tyrosine
tyrosine phosphatase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/037514
Other languages
English (en)
Other versions
WO2005047530A2 (fr
Inventor
Steven A Goldman
Fraser J Sim
Karen Chandross
Jean Merrill
Sridaran Natesan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of WO2005047530A2 publication Critical patent/WO2005047530A2/fr
Publication of WO2005047530A3 publication Critical patent/WO2005047530A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux procédés servant à déterminer si un composé ou un agent peut ou non moduler l'activité d'un récepteur de protéine tyrosine phosphatase (PTPRκ).
PCT/US2004/037514 2003-11-10 2004-11-09 Procede de dosage de composes modulant l'activite du recepteur zeta de proteine tyrosine phosphatase (ptpr$g(j)) Ceased WO2005047530A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59856504P 2003-11-10 2003-11-10
US60/598,565 2004-08-03

Publications (2)

Publication Number Publication Date
WO2005047530A2 WO2005047530A2 (fr) 2005-05-26
WO2005047530A3 true WO2005047530A3 (fr) 2005-07-28

Family

ID=34590521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037514 Ceased WO2005047530A2 (fr) 2003-11-10 2004-11-09 Procede de dosage de composes modulant l'activite du recepteur zeta de proteine tyrosine phosphatase (ptpr$g(j))

Country Status (1)

Country Link
WO (1) WO2005047530A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204816D0 (en) * 2012-03-19 2012-05-02 Brainco Biopharma S L Transgenic animal model of mood disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018308A1 (fr) * 1993-02-10 1994-08-18 New York University NOUVELLE PHOSPHOTYROSINE PHOSPHATASE-β DE TYPE RECEPTEUR
WO2001064944A1 (fr) * 2000-02-29 2001-09-07 Barnes-Jewish Hospital Modulation de la signalisation de la pleiotrophine au moyen de la proteine tyrosine phosphatase beta/zeta du type recepteur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018308A1 (fr) * 1993-02-10 1994-08-18 New York University NOUVELLE PHOSPHOTYROSINE PHOSPHATASE-β DE TYPE RECEPTEUR
WO2001064944A1 (fr) * 2000-02-29 2001-09-07 Barnes-Jewish Hospital Modulation de la signalisation de la pleiotrophine au moyen de la proteine tyrosine phosphatase beta/zeta du type recepteur

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOLDMAN S: "Glia as neural progenitor cells", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 11, November 2003 (2003-11-01), pages 590 - 596, XP004469787, ISSN: 0166-2236 *
HARROCH SHEILA ET AL: "A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.", NATURE GENETICS. NOV 2002, vol. 32, no. 3, November 2002 (2002-11-01), pages 411 - 414, XP002329234, ISSN: 1061-4036 *
RANJAN M ET AL: "Regulation of tyrosine phosphorylation and protein tyrosine phosphatases during oligodendrocyte differentiation", MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 7, no. 5, 1996, pages 404 - 418, XP002329233, ISSN: 1044-7431 *
SIM F J ET AL: "Transcriptional identification of acutely isolated progenitor cells of the adult human subcortical white matter.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 674.4 URL - http://sf, XP001206418 *

Also Published As

Publication number Publication date
WO2005047530A2 (fr) 2005-05-26

Similar Documents

Publication Publication Date Title
AU2002316137A1 (en) Method of determining protein interaction inhibitors
AU2002360691A1 (en) Method and system for analyzing and predicting the behavior of systems
AU2002256619A1 (en) Method for identifying herbicidally active substances
WO2004020458A3 (fr) Tests et compositions d'identification d'agents modulant l'activite d'agents de desubiquitination
AU2002302243A1 (en) Method for determination of co-occurences of attributes
WO2002086062A3 (fr) Procedes de criblage de composes modulant l'activite des recepteurs d'hormones
WO1999019513A3 (fr) Procedes pour la detection de composes modulant l'activite d'un recepteur d'acide lysophosphatidique (lpa)
WO2004079326A3 (fr) Bioanalyse de lymphome kinase anaplasique, reactifs et compositions en contenant
AU2002343794A1 (en) Data relay, method for determining transmission destination of acquired request, and program for realizing the method by computer
DK1456404T3 (da) Fremgangsmåde til at bestemme difibrotids biologiske aktivitet
AU2001267485A1 (en) Method for the analysis of picomole amounts of carbohydrates
AU2003224297A1 (en) System and method for multiparameter analysis of analytes
WO2005047530A3 (fr) Procede de dosage de composes modulant l'activite du recepteur zeta de proteine tyrosine phosphatase (ptpr$g(j))
AU2001267922A1 (en) Method of assaying the function of fc fragment of antibody
FR2842305B1 (fr) Procede de determination de l'independance d'un systeme electrochimique
WO2001012838A3 (fr) Composes modulateurs de l'activite d'un recepteur d'acide lysophosphatidique (lpa)
AU2003269635A1 (en) An analyzer for the simultaneous enzymatic detection of closely related analytes
WO2002066656A3 (fr) Detection de conformation de proteines a l'aide d'un systeme de rapporteurs d'ubiquitine dedoublee
WO2000036101A3 (fr) Proteine de cassette de liaison a l'atp responsable de la resistance aux cytotoxines
EP1241182A3 (fr) Analyse d'activité agoniste et antagoniste contre le récepteur de cytokinine
WO2003100439A3 (fr) Recepteur et methodes de criblage
AU2002216423A1 (en) Method of assaying agglutination reaction
WO2004056961A9 (fr) Procedes d'identification de composes qui modulent l'activite d'une proteine
AU2003293303A1 (en) Screening assay for identifying agents that modulate pak kinase or cd45 tyrosine phosphatase activity
HK1068948A (en) Method for predicting the sensitivity of chemotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase